

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: markspencer

Timestamp: [year=2010; month=4; day=23; hr=13; min=44; sec=55; ms=11;]

=====

Application No: 10553686 Version No: 1.0

Input Set:

Output Set:

Started: 2010-04-16 13:22:43.504
Finished: 2010-04-16 13:22:44.123
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 619 ms
Total Warnings: 6
Total Errors: 0
No. of SeqIDs Defined: 12
Actual SeqID Count: 12

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)

SEQUENCE LISTING

<110> Lowenstein, Charles
Matsushita, Kenji
Morrell, Craig

<120> Inhibitors of N-Ethylmaleimide Sensitive Factor

<130> 07410010aa

<140> 10553686

<141> 2010-04-16

<150> US 60/463,395

<151> 2003-04-15

<150> PCT/US2004/011655

<151> 2004-04-15

<160> 12

<170> PatentIn version 3.5

<210> 1

<211> 11

<212> PRT

<213> Human immunodeficiency virus

<400> 1

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
1 5 10

<210> 2

<211> 36

<212> PRT

<213> Artificial

<220>

<223> fusion peptide

<400> 2

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly Gly Leu
1 5 10 15

Asp Lys Glu Phe Asn Ser Ile Phe Arg Arg Ala Phe Ala Ser Arg Val
20 25 30

Phe Pro Pro Glu
35

<210> 3
<211> 35
<212> PRT
<213> Artificial

<220>
<223> fusion peptide

<400> 3

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly Glu Asn
1 5 10 15

Ser Phe Arg Phe Leu Ala Asp Ile Phe Pro Ala Lys Ala Phe Pro Val
20 25 30

Arg Phe Glu
35

<210> 4
<211> 22
<212> PRT
<213> Homo sapiens

<400> 4

Gly Leu Asp Lys Glu Phe Asn Ser Ile Phe Arg Arg Ala Phe Ala Ser
1 5 10 15

Arg Val Phe Pro Pro Glu
20

<210> 5
<211> 34
<212> PRT
<213> Artificial

<220>
<223> fusion peptide

<400> 5

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly Gly Ser
1 5 10 15

Val Ala Phe Ser Leu Pro Gln Arg Lys Trp Ala Gly Leu Ser Ile Gly
20 25 30

Gln Glu

<210> 6
<211> 34
<212> PRT
<213> Artificial

<220>
<223> fusion peptide

<400> 6

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly Ala Leu
1 5 10 15

Tyr Ser Phe Asp Lys Ala Lys Gln Cys Ile Gly Thr Met Thr Ile Glu
20 25 30

Ile Asp

<210> 7
<211> 35
<212> PRT
<213> Artificial

<220>
<223> fusion peptide

<400> 7

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly Lys Gly
1 5 10 15

Ile Leu Leu Tyr Gly Pro Pro Gly Cys Gly Lys Thr Leu Leu Ala Arg
20 25 30

Gln Ile Gly
35

<210> 8
<211> 36
<212> PRT
<213> Artificial

<220>
<223> fusion peptide

<400> 8

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly Leu Leu

1 5 10 15

Asp Tyr Val Pro Ile Gly Pro Arg Phe Ser Asn Leu Val Leu Gln Ala
 20 25 30

Leu Leu Val Leu
 35

<210> 9
<211> 20
<212> PRT
<213> Homo sapiens

<400> 9

Gln Ser Val Ile Ser Pro Asp Trp Asp Phe Thr Lys Met Gly Ile Gly
1 5 10 15

Gly Leu Asp Lys
 20

<210> 10
<211> 22
<212> PRT
<213> Homo sapiens

<400> 10

Gly Leu Asp Lys Glu Phe Asn Ser Ile Phe Arg Arg Ala Phe Ala Ser
1 5 10 15

Arg Val Phe Pro Pro Glu
 20

<210> 11
<211> 20
<212> PRT
<213> Homo sapiens

<400> 11

Thr Gly Lys Thr Leu Ile Ala Arg Lys Ile Gly Thr Met Leu Asn Ala
1 5 10 15

Arg Glu Pro Lys
 20

<210> 12

<211> 19
<212> PRT
<213> Homo sapiens

<400> 12

Lys	Tyr	Val	Gly	Glu	Ser	Glu	Ala	Asn	Val	Arg	Arg	Leu	Phe	Ala	Glu
1				5					10					15	

Ala Glu Glu